IQVIA Holdings Inc. (NYSE:IQV) has been identified as one of the top 10 Best Consensus Buy-Rated Stocks to Invest in, according to a report by Morgan Stanley. Despite lowering its price target on IQVIA Holdings Inc. to $240 from $265, the financial services firm maintained an Overweight rating on the stock following the company’s quarterly results.
In a significant development on February 10, 2026, IQVIA Holdings Inc. announced a collaboration with the Duke Clinical Research Institute with the aim of advancing clinical research in obesity and related cardiometabolic trials. Jeffrey Spaeder, Chief Medical and Scientific Officer at IQVIA, emphasized that this partnership is designed to establish a new standard for collaboration between life science service companies and academic research organizations. The collaboration is expected to accelerate clinical trial planning and delivery, ultimately improving trial efficiency and speeding up the process of bringing therapies to patients.
Following the release of its fourth-quarter results on February 5, 2026, IQVIA reported revenue of $4.36 billion, surpassing the $4.08 billion consensus estimate. CEO Ari Bousbib highlighted the company’s strong performance across all segments in 2025, with near double-digit revenue and EPS growth. He noted that the company recorded its strongest quarter of the year in R&DS net bookings. Bousbib attributed this performance to expanded go-to-market efforts, operational discipline, and investments in artificial intelligence, which supported growth in both the commercial and clinical businesses.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries across various regions. While IQVIA presents itself as a promising investment opportunity, some investors may find greater upside potential and lower downside risk in certain AI stocks. For those seeking an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock may offer valuable insights.
In conclusion, IQVIA Holdings Inc. continues to make strides in the healthcare and life sciences sectors through strategic partnerships and strong financial performance. Investors are advised to conduct thorough research and consider their investment goals before making any decisions.
